Ozcete O, Banerjee A, Kaeser P
Mol Psychiatry. 2024; 29(11):3680-3693.
PMID: 38789677
PMC: 11540752.
DOI: 10.1038/s41380-024-02608-3.
Gregoriou G, Patel S, Pyne S, Winters B, Bagley E
J Neurosci. 2023; 43(10):1668-1681.
PMID: 36781220
PMC: 10010477.
DOI: 10.1523/JNEUROSCI.1317-22.2022.
Bozkurt B, Nair A, Misra A, Scott C, Mahar J, Fedson S
JACC Basic Transl Sci. 2023; 8(1):88-105.
PMID: 36777165
PMC: 9911324.
DOI: 10.1016/j.jacbts.2022.05.010.
Fricker L, Margolis E, Gomes I, Devi L
Mol Pharmacol. 2020; 98(2):96-108.
PMID: 32487735
PMC: 7330675.
DOI: 10.1124/mol.120.119388.
Arendse L, Danser A, Poglitsch M, Touyz R, Burnett Jr J, Llorens-Cortes C
Pharmacol Rev. 2019; 71(4):539-570.
PMID: 31537750
PMC: 6782023.
DOI: 10.1124/pr.118.017129.
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.
Volpe M, Carnovali M, Mastromarino V
Clin Sci (Lond). 2015; 130(2):57-77.
PMID: 26637405
PMC: 5233571.
DOI: 10.1042/CS20150469.
Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
Volpe M, Tocci G, Battistoni A, Rubattu S
High Blood Press Cardiovasc Prev. 2015; 22(3):241-6.
PMID: 26100410
DOI: 10.1007/s40292-015-0112-5.
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.
Mangiafico S, Costello-Boerrigter L, Andersen I, Cataliotti A, Burnett Jr J
Eur Heart J. 2012; 34(12):886-893c.
PMID: 22942338
PMC: 3604644.
DOI: 10.1093/eurheartj/ehs262.
The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?.
Nalivaeva N, Belyaev N, Zhuravin I, Turner A
Int J Alzheimers Dis. 2012; 2012:383796.
PMID: 22900228
PMC: 3412116.
DOI: 10.1155/2012/383796.
Active site mutations change the cleavage specificity of neprilysin.
Sexton T, Hitchcook L, Rodgers D, Bradley L, Hersh L
PLoS One. 2012; 7(2):e32343.
PMID: 22384224
PMC: 3285688.
DOI: 10.1371/journal.pone.0032343.
Natriuretic peptide metabolism, clearance and degradation.
Potter L
FEBS J. 2011; 278(11):1808-17.
PMID: 21375692
PMC: 4495883.
DOI: 10.1111/j.1742-4658.2011.08082.x.
CD10-bearing fibroblast inhibits matrigel invasive potency of interleukin-1α-producing squamous cell carcinoma by diminishing substance P levels in the tumor microenvironment.
Xie L, Moroi Y, Tsuji G, Liu M, Hayashida S, Takahara M
Cancer Sci. 2010; 101(12):2570-8.
PMID: 20874839
PMC: 11158981.
DOI: 10.1111/j.1349-7006.2010.01735.x.
On the origin of the catalytic power of carboxypeptidase A and other metalloenzymes.
Kilshtain A, Warshel A
Proteins. 2009; 77(3):536-50.
PMID: 19480013
PMC: 2767396.
DOI: 10.1002/prot.22466.
Tolerance to repeated morphine administration is associated with increased potency of opioid agonists.
Ingram S, Macey T, Fossum E, Morgan M
Neuropsychopharmacology. 2007; 33(10):2494-504.
PMID: 18046309
PMC: 5688517.
DOI: 10.1038/sj.npp.1301634.
New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection.
Turner A, Nalivaeva N
Int Rev Neurobiol. 2007; 82:113-35.
PMID: 17678958
PMC: 7112344.
DOI: 10.1016/S0074-7742(07)82006-X.
In vitro methionine5-enkephalin degradation kinetics by human brain preparations.
Mosnaim A, Nguyen T, Tse R, Puente J, Couceyro P, Wolf M
Neurochem Res. 2007; 33(1):81-6.
PMID: 17676390
DOI: 10.1007/s11064-007-9418-6.
Endogenous signaling complexity in neuropeptides- leucine- and methionine-enkephalin.
Lukiw W
Cell Mol Neurobiol. 2006; 26(4-6):1003-10.
PMID: 16802191
PMC: 11520610.
DOI: 10.1007/s10571-006-9100-6.
Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes.
Macours N, Poels J, Hens K, Francis C, Huybrechts R
Int Rev Cytol. 2004; 239:47-97.
PMID: 15464852
PMC: 7126198.
DOI: 10.1016/S0074-7696(04)39002-9.
Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin.
Rose C, Voisin S, Gros C, Schwartz J, Ouimet T
Biochem J. 2002; 363(Pt 3):697-705.
PMID: 11964170
PMC: 1222522.
DOI: 10.1042/0264-6021:3630697.
Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide.
Fischer H, Zernig G, Hauser K, Gerard C, Hersh L, Saria A
J Mol Neurosci. 2002; 18(1-2):129-34.
PMID: 11931342
DOI: 10.1385/JMN:18:1-2:129.
